Novel therapeutic strategies for patients with triple-negative breast cancer

Zhang, Junfei; Liu, Jia; Wang, Yu; Zhang, Bin

doi:10.2147/ott.s105716

Cited by 25 publications

(19 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with TNBC typically have a worse prognosis in terms of relapse-free survival and overall survival compared with patients of a primarily non-TNBC subtype [4]. While TNBC patients may respond initially to anthracycline/taxane-based adjuvant chemotherapies, they often develop visceral or CNS metastasis [5]. TNBC patients have an increased likelihood of experiencing a distant recurrence compared with other breast cancer patients, which peak at 3-years post-treatment, and the majority of deaths in TNBC occur within 5 years of diagnosis [6].…”

mentioning

confidence: 99%

“…Frail older patients may benefit from chemotherapy; however, in most cases, these patients are generally considered for palliative and hospice care [12]. Recent developments in the treatment of mTNBC have focused on targeted therapies including targeting receptors such as the androgen receptor and the epidermal growth factor receptor, inhibiting enzymes/proteins such as the ADP ribose polymerase and the glycoprotein NMB, or inhibiting a molecular pathway such as the PI3K/Akt/mTOR [5]. These targeted therapies are quickly changing the treatment paradigm for mTNBC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Overall Survival, Costs and Healthcare Resource Use by Number of Regimens Received in Elderly Patients with Newly Diagnosed Metastatic Triple-Negative Breast Cancer

et al. 2019

View full text Add to dashboard Cite

This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancer patients. Materials & methods: Patients (≥66 years) with metastatic triple-negative breast cancer were identified from the SEER-Medicare database. Treatment patterns were defined in terms of first, second and third or more regimens. Healthcare resource use and costs were reported over the follow-up period and over the treatment duration of each regimen. Results: A total of 51% of patients did not receive chemotherapy. Taxanes were most commonly used. Median survival was 7 months. The mean cumulative (per patient per month

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Overall Survival, Costs and Healthcare Resource Use by Number of Regimens Received in Elderly Patients with Newly Diagnosed Metastatic Triple-Negative Breast Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…But with the ability of BRCA1/2 silencing from hypermethylation origin, the BRCA1 influence can exceed much higher than 25%. Although there are novel treatments being developed the nature of TNBC leaves patients with the high rate of incidence, while still not having a definitive therapeutic target [55,56]. What is known about TNBC today should help pave the way for decreased cancer diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors contributing to Methylation Shifts in BRCA1 and associated genes in African Americans with Triple Negative Breast Cancer

Marsh¹,

Chandra²

2017

Med-Science

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) remains one of the most lethal breast cancers while only accounting for 10-20% of all breast cancers. Mortality rates are a staggering 50%, with high likelihood of metastasis to other tissues if left untreated. This is due to this cancer's heterogeneous nature and differentiation from other breast cancers, negatively staining for common mutations in estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2). The patient population is shifted more towards African Americans (AA) with increased incidence and mortality rates. To date the nature of this statistic remains multifaceted with no clear therapeutic regiment. Through the identification of methylation as viable cause for TNBC, the exploration of environmental, genetic, and socioeconomic risk factors serve as an important aspect of overall mortality rate. This review seeks to investigate the relationship between AA with TNBC and potentially important DNA methylation markers that change in response to multiple risk factors.

show abstract

“…Breast cancer (BC) is the most common malignancy among females worldwide, and is a heterogeneous and multiplex disease with multiple pathogenic factors [15][16][17]. The 5-year survival of BC will be greatly improved if the disease is diagnosed at an early stage, yet the outcome of 15% of BC patients is still poor due to diagnosis at an advanced stage [18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

The Clinicopathological Significance and Correlative Signaling Pathways of an Autophagy-Related Gene, Ambra1, in Breast Cancer: a Study of 25 Microarray RNA-Seq Datasets and in-House Gene Silencing

Xiong

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The activating molecule in Beclin1-regulated autophagy (Ambra1) has been observed to be over-expressed in several cancers, but the clinical contribution of Ambra1 in breast cancer (BC) remains unknown. Hence, in this study, we conducted a comprehensive investigation into the expression, biological role, and underlying functional mechanism of Ambra1 in BC. Methods: Microarray and RNA-seq datasets providing Ambra1 expression data were obtained from Gene Expression Omnibus (GEO), ArrayExpress, Oncomine, and The Cancer Genome Atlas (TCGA). Both standard mean deviation (SMD) and summary receiver operating characteristic methods were employed to assess Ambra1 expression in BC. We then silenced Ambra1 in MDA-MB-231 cells and performed in vitro experiments to explore the biological effects of Ambra1 on BC cells. Furthermore, differentially expressed genes (DEGs) after Ambra1 knock-down were profiled with a microarray and overlapped with the genes correlated with Ambra1 from Multi Experiment Matrix (MEM) and genes similar to Ambra1 from Gene Expression Profiling Interactive Analysis. These overlapping genes were collected for further bioinformatics analyses to investigate the underlying molecular mechanism of Ambra1 in BC. Results: A total of 25 microarray and RNA-seq datasets involving 2460 breast cancer samples were included. The pooled results demonstrated that Ambra1 was markedly up-regulated in BC tissues (SMD=0.39, 95% CI=0.15–0.63; P=0.002), and the Ambra1 level was also significantly related to the progression of BC, especially metastasis status (P=0.004). In vitro experiments suggested that the proliferation of MDA-MB-231 cells transfected with Ambra1 short hairpin RNA (sh-RNA 2450) showed a decreasing trend at 48 h compared with the control (CK) group. However, apoptosis was similar in cells transfected with Ambra1 sh-RNAs and in the CK cells. Furthermore, we performed a microarray-based comparison of genes after Ambra1 knock-down. The 828 DEGs from microarray analysis were intersected with 4266 Ambra1 co-expressed genes from MEM. Eventually, the overlapped 183 genes were found to be enriched in several well-known cancer-related pathways, including the MAPK signaling pathway, chronic myeloid leukemia pathway, and VEGF signaling pathway. Conclusion: These results indicate that the level of Ambra1 up-regulation is clearly related to tumorigenesis and progression of BC, probably via influencing several vital pathways. However, this hypothesis needs to be validated with more in-depth experiments in the future.

show abstract

Novel therapeutic strategies for patients with triple-negative breast cancer

Cited by 25 publications

References 89 publications

Overall Survival, Costs and Healthcare Resource Use by Number of Regimens Received in Elderly Patients with Newly Diagnosed Metastatic Triple-Negative Breast Cancer

Overall Survival, Costs and Healthcare Resource Use by Number of Regimens Received in Elderly Patients with Newly Diagnosed Metastatic Triple-Negative Breast Cancer

Risk Factors contributing to Methylation Shifts in BRCA1 and associated genes in African Americans with Triple Negative Breast Cancer

The Clinicopathological Significance and Correlative Signaling Pathways of an Autophagy-Related Gene, Ambra1, in Breast Cancer: a Study of 25 Microarray RNA-Seq Datasets and in-House Gene Silencing

Contact Info

Product

Resources

About